An observational study in Cardiomyopathies, Cardiac Arrest and Cardiac Arrhythmias, sponsored by Idoven 1903 S.L.. Recruiting at 13 sites in 2 countries. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Idoven 1903 S.L. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Cardiomyopathies with a site in Spain — 13 open to participants now, 16 under way, 5 of them phase 3. Cardiomyopathies · Spain.
Among the 32 studies in Cardiomyopathies with a site in Spain, this one is the 2nd largest by planned enrollment of the 16 observational ones that give a count, is one of 5 that started in 2023, is one of 16 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 18th registered.
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
Browse Cardiomyopathies studies →13 of the 32 studies in Cardiomyopathies with a site in Spain are open now. Recruiting first, the newest first:
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Lexeo Therapeutics · Sites in Spain, United States, Brazil and 6 more countries
Ages 6+
Bayer · Sites in Spain, Austria, Belgium and 14 more countries
Ages 18+
Lexeo Therapeutics · Sites in Spain, United States, Brazil and 5 more countries
Ages 6+
Alnylam Pharmaceuticals · Sites in Spain, United States, Argentina and 33 more countries
Ages 18–85
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 4 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 10 · Phase 4 2
First in 2002; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,342 is above the median of 200 across 264 observational studies indexed under Cardiomyopathies.
Median enrollment 258 across the 16 interventional studies, 325 across the 16 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 32 have an industry lead sponsor. The 10 most frequent:
Idoven 1903 S.L. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Idoven 1903 S.L. has 1 study filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
6 of the studies in Cardiomyopathies with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05890716Idoven 1903 S.L.AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM) | 2026-12 |
| NCT07339007Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC)Observational Study to Validate a Family Physician Echocardiography Training Programme | 2026-12-31 |
| NCT06896266Hospital Universitario 12 de OctubreGenetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy | 2027-08 |
| NCT05981092Alexion Pharmaceuticals, Inc.A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) | 2027-08-12 |
Add all 6 to your calendar (.ics) → With an account.
Among the 32 studies in Cardiomyopathies with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
WILLEM is a multi-center, prospective and retrospective cohort study.
The study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:
The prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.
Cardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, >95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.
The WILLEM study is an investigator-initiated, multicenter, observational trial aiming to validate a cloud-based AI-powered ECG analysis platform to early diagnose and predict the behavior of cardiac abnormalities and cardiac diseases from patients admitted to cardiovascular units. Model-derived diagnosis will be compared with cardiology expert's diagnosis in a test dataset. Clinical outcomes will be included to assess model prediction capabilities: sensitivity, specificity and accuracy. In this observational study, patients will be randomly divided into two groups: (1) a training group to design new methodologies and algorithms; and (2) a test group to evaluate performance of methodologies aiming to avoid overfitting.
Willem™ AI-powered ECG analysis platform supports the analysis of cardiac electrical signals ≥ 10 seconds onwards obtained from devices in-clinic (E.g., 12-lead ECG devices at hospitals or primary care, telemetries, monitors) and at-home or telemedicine interfaces (E.g., Holter devices, event recorders, 6, 3, 2, 1-lead ECG wearables, textile electrodes and patches for mobile cardiac telemetry).
Patients recorded with a mid to long-term ECG device according to guidelines. ECG data (ECG must have been recorded according to the technical standards for the safety and essential performance of medical electrical equipment defined in EN 60601-2-47:2015.): 12-lead ECGs including rest electrocardiograms, stress ECG Test (exercise Electrocardiogram or treadmill test), Holter devices, long-duration Holter devices, event recorders, insertable cardiac monitors, 6,3,2,1-lead ECG wearables, textile electrodes and patches, smartwatches, cardiac monitors, cardiac telemetries, hemodynamic and electrophysiology recording system (i.e., polygraphs), automatic external defibrillator (AED), semi-automatic defibrillator (DESA), home telemonitoring systems and other similar devices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.
Diagnostic Test: AI-powered ECG analysis to detect cardiac arrhythmic episodes
Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record \>10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.
Diagnostic Test: AI-powered ECG analysis to detect cardiac arrhythmic episodes
ECG recording and processing by AI platform
Detection of cardiac arrhythmias and cardiac patterns in the electrocardiographic signals
Willem™ heart rhythm and cardiac pattern performance compared to standard manually performed cardiologist diagnosis.
Time frame: real time to 7 minutes
Survival at follow-up
Patients alive at the time of follow-up
Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
MACCE rates defined as cardiovascular and cerebrovascular events during the follow up
Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)
Re-hospitalization
Number of Re-hospitalizations during the follow up.
Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)
Change in quality of life
European Quality of Life-5 Dimensions (EQ-5D) index an utility scores anchored at 0 for death and 1 for perfect health.
Time frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients)
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Nov 2026 → Dec 2026 and completion Nov 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idoven 1903 S.L.